GLP-1 Drugs and 8 Healthy Lifestyle Habits May Lower Cardiovascular Risk
A large observational study of 98,261 U.S. veterans with type 2 diabetes found that using GLP‑1 receptor agonists together with six to eight healthy lifestyle habits lowered major adverse cardiovascular events (MACE) by 43% compared with low‑habit, non‑GLP‑1 users. Both the medication and the habits independently reduced risk, with full adherence to all eight habits cutting MACE by 60% and GLP‑1 use alone trimming risk by 16%. The eight habits examined included diet quality, exercise, smoking avoidance, adequate sleep, moderate alcohol, stress management, social connection, and no opioid‑use disorder. Researchers caution that the veteran‑centric, predominantly white male sample may limit broader generalizability.
Vinay Prasad, Controversial FDA Leader, to Again Depart Agency
Vinay Prasad, the controversial head of the FDA's Center for Biologics Evaluation and Research, will leave the agency in April after a tumultuous year marked by stricter vaccine guidelines and a new pathway for ultra‑rare gene therapies. His tenure saw...
New Eli Lilly Platform To Expand Obesity Drug Options For Employers
Eli Lilly launched an Employer Connect platform on March 5, linking more than 15 independent program administrators with a nationwide pharmacy and telehealth network to broaden discounted access to its obesity drugs, notably the GLP‑1 Zepbound (tirzepatide) pen. The service targets employer‑sponsored...
As Peptides Go Mainstream, USP and Matter More Than Ever
Peptide therapies have moved from niche compounding to mainstream outpatient care, driven by telehealth platforms and rapid market growth. This expansion has attracted regulatory attention, with state boards and courts increasingly referencing USP and as compliance benchmarks. Non‑sterile peptide...
5 FDA Developments From February: Kinase Inhibitors, GLP-1s, and a New Approval Pathway
In February 2026 the FDA approved a suite of targeted therapies, including the HER2‑mutant NSCLC kinase inhibitor zognertinib and the first all‑oral acalabrutinib‑venetoclax combo for CLL/SLL, as well as a BRAF‑targeted encorafenib regimen for metastatic colorectal cancer. A portable tumor‑treating‑fields...
Market Turmoil Is Hitting Most Traditional Safe Havens. UBS Says This Is the Place to Hide
Geopolitical tensions between the U.S., Israel and Iran have rattled traditional safe‑haven assets, with gold and consumer staples slipping as oil prices breach $100 per barrel. UBS recommends pharmaceutical stocks as the new defensive refuge, citing their inverse link to...
EpiciphAI: Reading Disease States From Blood’s Epigenetic Fingerprints
EpiciphAI, a Chinese pre‑seed biotech, is building a liquid biopsy that reads histone modifications on cell‑free chromatin to pinpoint a fragment’s tissue of origin and its disease state. Unlike most epigenetic tests that focus on DNA methylation, this platform targets...
Canada and CSL Seqirus – a Global Leader in Influenza Vaccines, Agree on New Pandemic Preparedness Contract
Canada’s Public Health Agency has signed a new agreement with CSL Seqirus to provide millions of doses of adjuvanted cell‑based influenza vaccine in the event of a WHO‑declared pandemic. The contract replaces a previous egg‑based arrangement and builds on the...
STAT+: The FDA, Urged to Avoid Controversy, Creates a New Headache with Attack Against UniQure
The FDA staged a media call where an anonymous senior official publicly criticized UniQure’s experimental Huntington’s disease gene therapy. The official, identified only as a practicing hematology‑oncology professor, framed his comments as serving the public interest while hinting at personal...
Recapping AAAAI 2026: Updates on Remibrutinib and Innovative Treatments for Food Allergy, Atopic Disease, Asthma
At AAAAI 2026, Novartis presented data confirming remibrutinib’s rapid and sustained efficacy in chronic spontaneous urticaria, with a 25 mg BID dose delivering significant UAS7 reductions. Phase 2 trials also demonstrated the BTK inhibitor’s potential in peanut allergy, achieving 86.7% tolerance at...
Drug Shortages | Additional News and Information
The FDA’s Drug Shortages portal aggregates letters, temporary import authorizations, and annual reports that detail current and historic medication scarcities. Recent communications include temporary import permits for Lederle Leucovorin, Tafenoquine, and Physostigmine to bridge supply gaps. The site also hosts...
Check Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers
The article outlines the legal requirement that U.S. wholesale drug distributors and third‑party logistics providers (3PLs) must hold a valid state license to handle prescription medications. It warns that unlicensed or unauthorized partners can expose patients to counterfeit, stolen, or...
Medochemie's Green Energy Transition Signals New Era for Pharmaceutical Manufacturing
Medochemie, Cyprus’s largest generic drug maker, has powered all nine of its GMP‑certified manufacturing sites with 100% renewable electricity as of 1 October 2025, covering roughly 18 million kWh annually and eliminating thousands of tonnes of CO₂. The transition aligns the firm with tightening...
J&J Wins Third National Priority Approval for Multiple Myeloma Combo
Johnson & Johnson’s Tecvayli and Darzalex combination received FDA approval for second‑line multiple myeloma treatment, marking the third drug cleared under the Commissioner’s National Priority Voucher (CNPV) program. The decision was rendered in just 55 days after J&J’s filing, thanks...
Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection
The FDA has issued a draft Level 1 guidance (Docket FDA‑2025‑D‑1504) titled “Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection.” The document targets both foreign and domestic manufacturers of human and animal drugs regulated by CDER,...
From MFN to IRA, Experts Warn of a System Under Pressure in Wide-Ranging Policy Webinar
The March 3, 2026 AJMC/MHE webinar examined the Trump administration’s Great Healthcare Plan, focusing on most‑favored‑nation (MFN) drug pricing, the lapse of ACA marketplace subsidies, and the Inflation Reduction Act’s (IRA) impact on community oncology. Sixteen manufacturers have voluntarily adopted MFN pricing,...
Biopharma’s Recent String of CEO Splits
Three biopharma firms—Bavarian Nordic, Sarepta Therapeutics, and Alkermes—announced the departures of long‑standing CEOs, prompting short‑term share declines. Bavarian Nordic’s Paul Chaplin steps down after a blocked $3 billion buyout, while Sarepta’s Doug Ingram leaves amid family health issues and recent product...
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Immuneering Corporation announced its 2025 financial results, highlighting a 64% overall survival rate at 12 months for atebimetinib plus modified gemcitabine/nab‑paclitaxel in first‑line pancreatic cancer. The company secured FDA and EMA alignment on the design of its pivotal Phase 3 MAPKeeper 301...
TaiGen Completes Enrolment and Doses First Patient with Insilico Medicine’s ISM4808 in P-I Trial
Insilico Medicine and TaiGen announced that enrollment for the Phase‑I trial of ISM4808, an AI‑designed therapy for CKD‑related anemia, is now complete and the first patient has been dosed. The study comprises single‑ascending‑dose and multiple‑ascending‑dose cohorts evaluating safety and pharmacokinetics...
PE Eyes Growth Opportunities in Active Pharmaceutical Ingredients: 5 Deals
Private equity firms are actively pursuing growth in the active pharmaceutical ingredient (API) sector, with five recent transactions highlighted by Astorg, EQT, New Mountain Capital and TA Associates. The deals involve both acquisitions and divestitures of API manufacturing assets, reflecting...
Magnetic Nanoparticles Could Make Doxorubicin Delivery More Precise
Researchers have engineered a magnetic nanocarrier (IO@MBD) that combines γ‑Fe₂O₃ nanoparticles with a melamine‑based dendrimer to deliver doxorubicin. The platform achieves roughly 17 wt% drug loading, remains dispersible in water, and releases the drug preferentially under acidic conditions typical of tumor...
How the AI Shift Is Happening Now in Data Management
The latest generation of AI‑driven tools is transforming clinical trial data management by automating the build of electronic data capture (EDC) systems. Solutions such as CRScube’s AI‑led EDC builder can convert a PDF protocol into a structured database in hours...
Johnson & Johnson Reports the US FDA Approval of Tecvayli + Darzalex Faspro for R/R Multiple Myeloma
Johnson & Johnson announced FDA approval of the Tecvayli (teclistamab) and Darzalex Faspro (subcutaneous daratumumab with hyaluronidase) combination for adults with relapsed/refractory multiple myeloma who have received at least one prior line of therapy. The approval is grounded in the Phase III...
Seqster Unveils 1-Click DataLake for Clinical Trials
Seqster has introduced 1‑Click DataLake, a real‑world data platform that aggregates anonymized electronic health‑record information from over 150 million patients and 200,000 clinicians across the United States. The solution delivers real‑time, longitudinal patient journeys to speed trial design, feasibility assessments, and...
Liberate Bio Gains Licences for Myeloid-Specific CAR Design Patents
Liberate Bio announced it has secured both exclusive and non‑exclusive licenses for patents covering chimeric antigen receptor (CAR) designs specifically engineered for myeloid cells such as monocytes and macrophages. The patents, obtained from Carisma Therapeutics and the University of Pennsylvania,...
How the ‘Holy Grail’ Weight Loss Pill Became a Reality, and What Comes Next
The pharmaceutical industry has finally delivered an oral GLP‑1 weight‑loss pill, with Novo Nordisk launching an oral version of Wegovy earlier this year. Eli Lilly’s oral GLP‑1 candidate, orforglipron, is expected to receive approval imminently. Oral formulations overcome the injection barrier that...
Reversing Tumor Immunosuppression with Next-Gen GPCR Modulation
Kainova Therapeutics, formerly Domain Therapeutics, announced a Series B funding round to advance its next‑generation GPCR‑modulating platform aimed at reversing tumor immunosuppression. The rebrand signals a strategic shift toward a broader oncology focus, leveraging GPCR pathways that control immune cell trafficking....
Harrison.ai Secures the US FDA 510(k) Clearance for Acute Infarct Triage on Non-Contrast CT Brain
Harrison.ai has received U.S. FDA 510(k) clearance for its Acute Infarct Triage software, which analyzes non‑contrast CT brain scans to identify acute ischemic strokes. In validation studies the algorithm achieved roughly 89% sensitivity on thin‑slice CT and 86% on thicker...
Roche and Zealand Pharma Report P-II (ZUPREME-1) Trial Data on Petrelintide in Obesity
Roche and Zealand Pharma disclosed Phase‑II (ZUPREME‑1) results for petrelintide, an amylin‑analog injected weekly, in 493 overweight or obese adults (mean BMI 37 kg/m²) with weight‑related comorbidities. The trial evaluated five dose levels against placebo over 42 weeks and met its primary endpoint,...
Combination GLP-1 Therapy Reduces Fat Mass While Preserving Lean Muscle in Adults with Obesity
A recent double‑blind trial found that a combination of two GLP‑1 receptor agonists cut fat mass significantly while sparing lean muscle in adults with obesity. Over 24 weeks, participants lost an average of 5 % body fat, with lean mass decline...
Promising Henlus Data Tripped up by Psychedelic Trial Design Dilemma
Helus Pharma reported Phase II data for its psychedelic candidate HLP004, indicating symptom improvement in generalized anxiety disorder patients for up to six months. However, the trial’s low‑dose active control arm showed similar efficacy, making it difficult to isolate the...
Promising Helus Data Tripped up by Psychedelic Trial Design Dilemma
Helus Pharma reported Phase II data for its psychedelic candidate HLP004 in generalized anxiety disorder, showing symptom improvement lasting six months. However, the trial’s active low‑dose control produced outcomes similar to the therapeutic dose, making it difficult to isolate the drug’s...
Degenerating Tanycytes Disrupt Tau Removal, Shaping Alzheimer’s Progression
Researchers from Kyoto University and INSERM identified tanycytes as a previously unknown conduit that clears tau protein from cerebrospinal fluid into the bloodstream. In rodent and cellular models, blocking vesicular transport in these cells dramatically slowed tau efflux and worsened...
Advanced Vaccine Manufacturing in Australia to Supply Canada with 15 Million Pandemic Doses
Australian biotech firm CSL Seqirus has secured a contract with Canada’s Public Health Agency to deliver up to 15 million doses of a cell‑based, adjuvanted pandemic influenza vaccine if the WHO declares a pandemic. The doses will be manufactured at CSL...
![[Comment] Pimicotinib: A New Agent for an Orphan Disease](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/5b160e8a2b2821c82aa66047ca629679.webp)
[Comment] Pimicotinib: A New Agent for an Orphan Disease
Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive neoplasm driven by CSF‑1 over‑expression. The phase 3 MANEUVER trial evaluated pimicotinib, a selective CSF1R kinase inhibitor, against placebo in patients with inoperable or relapsed diffuse‑type TGCT. Results demonstrated statistically significant...
![[Correspondence] Changes in Paracetamol and Leucovorin Use After a White House Briefing](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/59b0c8a4048a3d105c9221755df21495.webp)
[Correspondence] Changes in Paracetamol and Leucovorin Use After a White House Briefing
The White House briefing on Sept 22 2025 linking prenatal acetaminophen to autism and promoting leucovorin was followed by an interrupted‑time‑series analysis of the Epic Cosmos database. Emergency‑department orders for paracetamol among pregnant women fell 10% (OER 0.90) while use among non‑pregnant women showed...
Asia Deals Aim for First-in-Class Biology, with at Least Four Deals for New Targets
Asian biotech firms outside China announced 72 deals in 2024‑25, emphasizing first‑in‑class assets over me‑better or me‑too programs. At least four transactions involve novel targets such as CNTN4, GPR52, MTARC1 and OK‑1, spanning new modalities and indications. Global pharmaceutical companies...
Your GLP-1 Drugs May Also Have Yet Another Undiscovered Benefit
A new observational study of nearly 22,000 chronic‑migraine patients found that those who started GLP‑1 receptor agonists for diabetes or obesity experienced fewer severe migraine events than peers on the preventive drug topiramide. Over a 12‑month follow‑up, GLP‑1 users had...
FDA Issues RFI on In-Home Opioid Disposal Products
The FDA issued a Request for Information (RFI) on March 5, 2026, asking for public input about new standards for in‑home opioid disposal products. The agency is evaluating whether opioid manufacturers should be required to supply disposal systems directly through dispensers....
Therapeutic mRNA Reverses Genetic Infertility in Male Mouse Model
Scientists delivered naked Cldn11 messenger RNA directly into the testes of genetically infertile male mice, restoring Sertoli cell function and enabling spermatogenesis. The treatment produced viable sperm that generated healthy offspring via in‑vitro fertilization, without permanent germline alteration. The approach...
Activities Report of the Generic Drug Program (FY 2025) – FDARA Title VIII Sections 807 and 805
The FDA’s FY 2025 Generic Drug Program report details progress on abbreviated new drug applications (ANDAs) under priority review and competitive generic therapy (CGT) designations. By the fourth quarter, pending priority‑review ANDAs fell to 40, while CGT ANDAs awaiting FDA action...
Schrödinger Stock – A Dead Cat Bounce?
Schrödinger’s stock has plunged 88% over five years, leaving a sub‑$1 billion market cap. The company’s AI‑driven software segment posted 11% revenue growth in 2025 and aims for modest 12% growth in 2026, while shifting customers to cloud contracts that compress...
Patient-Focused Drug Development Glossary
The FDA released a comprehensive Patient‑Focused Drug Development (PFDD) glossary to standardize terminology across its guidance documents mandated by the 21st Century Cures Act and PDUFA VI. The glossary defines key concepts such as attributes, benefit‑risk assessment, clinical outcome assessments, patient‑reported...
Is Neurodegeneration a Systemic Metabolic Condition?
British biotech Vesalic reports a breakthrough that links amyotrophic lateral sclerosis (ALS) to a systemic metabolic dysfunction detectable in blood extracellular vesicles (EVs). The company says the EVs carry a toxic lipid cargo that harms motor neurons, and its blood‑based...
Psychedelics Are Placeholders for More Traditional Depression Therapies: Analysts
Psychedelic antidepressants are poised for FDA review this year, driven by strong investor and patient interest. William Blair analysts note that while Johnson & Johnson’s Spravato generated $1.7 billion in 2025 sales, psychedelics are unlikely to capture the entire treatment‑resistant depression market. Companies...
Alnylam Unites With Tenaya in Potential $1B+ Pact To Find New Genetic Heart Disease Targets
Alnylam Pharmaceuticals has signed a deal with Tenaya Therapeutics, providing $10 million upfront and the potential for up to $1.13 billion in milestones to discover up to 15 new genetic targets for heart disease. Tenaya will apply its modality‑agnostic platform to validate...
UniQure’s Path for Huntington’s Gene Therapy Clouded by Ethical Questions as Potential Phase 3 Looms
UniQure’s one‑time gene therapy AMT‑130 showed a 75% slowdown in Huntington’s disease progression in its Phase 1/2 trial, prompting expectations for a BLA filing in early 2026. The FDA, however, reversed its earlier stance and now requires a sham‑controlled Phase 3 study,...
Cryo-EM Drug Discovery Center in Bay Area Opened by Thermo Fisher Scientific
Thermo Fisher Scientific has opened a Cryo‑Electron Microscopy Drug Discovery Center in South San Francisco, offering pharmaceutical and biotech firms direct, hands‑on access to cutting‑edge cryo‑EM instrumentation. The facility is designed to accelerate structural insight generation, enabling faster, more cost‑effective...
At CNBC Cures, Becky Quick Leads Clarion Call for Rare Disease Research
The CNBC Cures Summit opened with Becky Quick urging families and innovators to accelerate rare‑disease research. Speakers highlighted a widening gap between rapid scientific breakthroughs—gene therapies, AI‑driven diagnostics, and modular “nodal biology”—and an aging regulatory framework. Leaders from Biogen, the...
PepGen’s Mid-Stage Myotonic Dystrophy Study Hit With ‘Surprise’ Pause
PepGen’s Phase 2 FREEDOM2 trial in myotonic dystrophy type 1 received a partial FDA clinical hold due to concerns over a sub‑chronic mouse study that showed blood‑pressure changes. The agency did not question the Phase 1 human data, and the company continues dosing...